Horizon Technology Finance (HRZN) Is At $10.51 Formed Wedge; TG Therapeutics, Inc. (TGTX) Covered By 8 Bulls

April 12, 2018 - By Annabelle Johnson

Among 8 analysts covering TG Therapeutics (NASDAQ:TGTX), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. TG Therapeutics had 21 analyst reports since August 12, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, October 6 by Brean Capital. The firm has “Buy” rating given on Monday, December 11 by H.C. Wainwright. The stock of TG Therapeutics, Inc. (NASDAQ:TGTX) earned “Buy” rating by H.C. Wainwright on Tuesday, November 14. FBR Capital maintained TG Therapeutics, Inc. (NASDAQ:TGTX) rating on Monday, December 11. FBR Capital has “Buy” rating and $21.5 target. The rating was maintained by H.C. Wainwright on Tuesday, March 7 with “Buy”. The stock of TG Therapeutics, Inc. (NASDAQ:TGTX) has “Buy” rating given on Monday, June 5 by Jefferies. The company was maintained on Friday, February 2 by FBR Capital. FBR Capital initiated the shares of TGTX in report on Tuesday, December 1 with “Outperform” rating. FBR Capital maintained the stock with “Buy” rating in Thursday, June 15 report. The rating was initiated by Suntrust Robinson on Friday, May 27 with “Buy”. See TG Therapeutics, Inc. (NASDAQ:TGTX) latest ratings:

21/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $38.0 Initiate
09/03/2018 Broker: FBR Capital Rating: Buy New Target: $27.0 Maintain
02/02/2018 Broker: FBR Capital Rating: Buy New Target: $21.5 Maintain
17/01/2018 Broker: FBR Capital Rating: Buy New Target: $21.5 Maintain
12/12/2017 Broker: Raymond James Rating: Buy
11/12/2017 Broker: H.C. Wainwright Rating: Buy New Target: $33.0 Maintain
11/12/2017 Broker: FBR Capital Rating: Buy New Target: $21.5 Maintain
01/12/2017 Broker: B. Riley & Co Rating: Buy New Target: $21.5 Maintain
30/11/2017 Broker: FBR Capital Rating: Buy New Target: $21.5
14/11/2017 Broker: H.C. Wainwright Old Rating: Buy New Rating: Buy Old Target: $18 New Target: $33 Reinitiate

Horizon Technology Finance Corporation (HRZN) formed wedge down with $10.19 target or 3.00% below today’s $10.51 share price. Horizon Technology Finance Corporation (HRZN) has $121.10M valuation. The stock decreased 0.10% or $0.01 during the last trading session, reaching $10.51. About 55,184 shares traded. Horizon Technology Finance Corporation (NASDAQ:HRZN) has declined 5.12% since April 12, 2017 and is downtrending. It has underperformed by 16.67% the S&P500.

TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the United States. The company has market cap of $1.02 billion. It develops TG-1101 , a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory non-HodgkinÂ’s lymphoma and chronic lymphocytic leukemia. It currently has negative earnings. The firm also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies.

The stock increased 6.46% or $0.85 during the last trading session, reaching $14. About 1.30 million shares traded. TG Therapeutics, Inc. (NASDAQ:TGTX) has risen 23.61% since April 12, 2017 and is uptrending. It has outperformed by 12.06% the S&P500.

Investors sentiment increased to 2 in Q4 2017. Its up 0.79, from 1.21 in 2017Q3. It increased, as 12 investors sold TG Therapeutics, Inc. shares while 14 reduced holdings. 17 funds opened positions while 35 raised stakes. 35.20 million shares or 0.20% more from 35.13 million shares in 2017Q3 were reported. Rhumbline Advisers has invested 0% in TG Therapeutics, Inc. (NASDAQ:TGTX). California Employees Retirement reported 106,400 shares stake. Senzar Asset Mgmt Ltd Liability Com invested in 1.36 million shares. Stoneridge Invest Ltd Co has 71,998 shares. Guggenheim Capital Ltd Liability Com holds 151,387 shares or 0% of its portfolio. Bank Of Montreal Can has invested 0% in TG Therapeutics, Inc. (NASDAQ:TGTX). Blackrock holds 0% or 3.41M shares. Alliancebernstein Lp holds 0% or 59,940 shares. Cibc World Markets invested 0% of its portfolio in TG Therapeutics, Inc. (NASDAQ:TGTX). Aqr Cap Lc holds 0% in TG Therapeutics, Inc. (NASDAQ:TGTX) or 46,537 shares. State Of Wisconsin Board invested 0% in TG Therapeutics, Inc. (NASDAQ:TGTX). Goldman Sachs Group Inc Inc reported 311,793 shares. University Of Notre Dame Du Lac reported 302,761 shares or 0.52% of all its holdings. Northern Tru accumulated 617,784 shares. Victory Capital Mgmt holds 0% of its portfolio in TG Therapeutics, Inc. (NASDAQ:TGTX) for 3,056 shares.

Since December 29, 2017, it had 0 insider buys, and 1 sale for $272,051 activity. On Friday, December 29 the insider Power Sean A sold $272,051.

Among 7 analysts covering Horizon Technology Finance (NASDAQ:HRZN), 1 have Buy rating, 1 Sell and 5 Hold. Therefore 14% are positive. Horizon Technology Finance has $14 highest and $11.0 lowest target. $12.38’s average target is 17.79% above currents $10.51 stock price. Horizon Technology Finance had 17 analyst reports since August 6, 2015 according to SRatingsIntel. Oppenheimer upgraded Horizon Technology Finance Corporation (NASDAQ:HRZN) on Thursday, March 10 to “Outperform” rating. The company was upgraded on Monday, August 21 by Compass Point. National Securities downgraded the stock to “Neutral” rating in Thursday, November 3 report. National Securities maintained the shares of HRZN in report on Wednesday, August 5 with “Buy” rating. Maxim Group maintained the stock with “Buy” rating in Wednesday, August 23 report. Oppenheimer maintained Horizon Technology Finance Corporation (NASDAQ:HRZN) on Thursday, August 3 with “Hold” rating. Raymond James upgraded the shares of HRZN in report on Tuesday, November 10 to “Outperform” rating. The firm has “Market Perform” rating by Raymond James given on Thursday, November 2. The stock of Horizon Technology Finance Corporation (NASDAQ:HRZN) earned “Underperform” rating by Raymond James on Thursday, August 3. The stock has “Perform” rating by Oppenheimer on Thursday, August 4.

Investors sentiment increased to 1.25 in 2017 Q4. Its up 0.25, from 1 in 2017Q3. It improved, as 4 investors sold Horizon Technology Finance Corporation shares while 8 reduced holdings. 9 funds opened positions while 6 raised stakes. 1.48 million shares or 2.55% less from 1.52 million shares in 2017Q3 were reported. Regions Finance holds 0% or 200 shares. 96,769 were accumulated by Hillsdale Incorporated. Horizon Ltd Limited Liability Company stated it has 0.02% in Horizon Technology Finance Corporation (NASDAQ:HRZN). Cambridge Investment Advsrs Inc invested in 0% or 10,774 shares. Founders Financial Securities Limited Liability Corporation accumulated 10,472 shares. Moreover, Barclays Public Ltd has 0% invested in Horizon Technology Finance Corporation (NASDAQ:HRZN). Shelton Cap Management holds 35,000 shares. Brown Advisory Securities Limited Liability invested in 19,950 shares. Asset Mngmt holds 0.06% or 310,191 shares in its portfolio. 19,300 were reported by California Employees Retirement System. Lsv Asset Mgmt invested 0% of its portfolio in Horizon Technology Finance Corporation (NASDAQ:HRZN). Macquarie Grp Limited, Australia-based fund reported 27,586 shares. Royal Bankshares Of Canada holds 21,369 shares or 0% of its portfolio. Millennium Management Ltd Liability Co owns 26,744 shares. Bridgeway Mngmt reported 0.02% of its portfolio in Horizon Technology Finance Corporation (NASDAQ:HRZN).

TG Therapeutics, Inc. (NASDAQ:TGTX) Institutional Positions Chart